Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17319652 | 1.00 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4CYP1A2CYP2D6 | |
| SCHEMBL4176760 | 1.00 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4CYP1A2CYP2D6 | |
| SCHEMBL11645304 | 0.82 | MAOA (0.38) | SLC6A3SLC6A2SLC6A4CYP1A2CYP2D6 | |
| SCHEMBL2494534 | 0.81 | SLC6A4 (0.53) | SLC6A3SLC6A2SLC6A4CYP1A2CYP2D6 | |
| SCHEMBL20203032 | 0.81 | SLC6A4 (0.53) | SLC6A3SLC6A2SLC6A4CYP1A2CYP2D6 | |
| SCHEMBL13272960 | 0.81 | SLC6A4 (0.53) | SLC6A3SLC6A2SLC6A4CYP1A2CYP2D6 | |
| SCHEMBL4777365 | 0.76 | SLC6A2 (0.47) | SLC6A3SLC6A2SLC6A4KCNH2 | |
| SCHEMBL12459508 | 0.75 | CACNA1F (0.39) | CYP1A2KCNH2CYP2C9 | |
| SCHEMBL1963366 | 0.75 | CACNA1F (0.39) | CYP1A2KCNH2CYP2C9 | |
| SCHEMBL3984947 | 0.73 | CYP19A1 (0.59) | SLC6A3SLC6A2SLC6A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160346249-A1 | USE OF AMITIFADINE, (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN METHODS AND COMPOSITIONS WITH ENHANCED EFFICACY AND REDUCED METABOLIC SIDE EFFECTS AND TOXICITY FOR TREATMENT OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346249-A1 | USE OF AMITIFADINE, (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN METHODS AND COMPOSITIONS WITH ENHANCED EFFICACY AND REDUCED METABOLIC SIDE EFFECTS AND TOXICITY FOR TREATMENT OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | CYP2D6, MAOB, HTR1A | SLC6A3 68/4885SLC6A2 97/4885SLC6A4 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.